Imugene Limited (AU:IMU) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Imugene Limited has announced that its allogeneic CAR T-cell therapy, azer-cel, will be showcased at the 2025 ASTCT Tandem Meetings in Hawaii. The presentation will highlight the therapy’s enhanced pharmacokinetic profile without compromising safety for patients with Diffuse Large B-Cell Lymphoma. This marks a significant step for Imugene in the field of immuno-oncology, potentially boosting investor confidence.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
